Istradefylline is a selective antagonist of the A2AR that was first approved in Japan (Nouriast®) and later in the US (Nourianz®) as adjuvant in the therapy of Parkinson’s disease [12,13,14,15,16]. This evidence concerns the gene ADORA2A and Parkinson disease.